FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 | |
|-------------|------|-------|--|
|-------------|------|-------|--|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Brazzell Romulus K | | | | | 2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [KALA] | | | | | | | | neck all app Direc | icable) | ng Per | son(s) to Iss 10% Ov Other (s | vner |
|--|--|--|---|-----------------|---|----------|---|--|----|--|-----------------|--|--|--|--|---|-------------|
| (Last) | (F | irst) (| (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 03/14/2023 | | | | | | | ^ below | below) SEE REMA | | | | |
| C/O KALA PHARMACEUTICALS, INC. | | | | 103 | 03/14/2023 | | | | | | | | OLL KI | L1 V1 7 1 | KKS | | |
| 1167 MASSACHUSETTS AVENUE | | | | | | | | | | | | | | | | | |
| (Street) | STON M | A (| 02476 | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | Lin | Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting | | | | | |
| (City) | (S | tate) (| (Zip) | | | | | | | | | | Perso | n | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| Date | | | Transaction ate onth/Day/Ye | Execution Date, | | Code (II | Transaction Disposed Of (D) (Instr. 3, 2) Code (Instr. 5) | | | | Benefic | es For ially (D) Following (I) (| | Ownership rm: Direct or Indirect (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | ٧ | Amount | (A) o (D) | r Price | Transa (Instr. 3 | ction(s) | | | (IIISti. 4) |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Ye | Code | action (Instr. | of Ex | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4) | e s Illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership t (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | | kpiration ate | Title | Amount or Number of Shares | | | | | |
| Stock Option (Right to Buy) | \$68.5 | 03/14/2023 | | A | | 576 | | (1)(2) | 01 | 1/03/2032 | Common Stock | 576 | \$0 | 576 | | D | |

Explanation of Responses:

- 1. On January 3, 2022, the Reporting Person was granted an option to purchase up to 2,160 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.
- 2. On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 576 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 432 shares of common stock underlying the option.

Remarks:

Head of Research and Development and Chief Medical Officer

/s/ Eric Trachtenberg, 03/15/2023 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.